|
|
Sorrento Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Scilex announced complete enrollment of its sp-103 Phase 2study to evaluate the safety and efficacy in subjects with acute low back pain. Top-line data from the Phase 2 study is expected in Q3-2023. |
|
|
return to message board, top of board |
